This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.5 (disorders of glycine metabolism) | Special Copayment Reduction: V117 (rare disease) |
| B. Synonyms | Sarcosinemia (SARDH deficiency), Hydroxyprolinemia (HOGA1-related), Hyperprolinemia type I (PRODH deficiency), Hyperprolinemia type II (ALDH4A1 deficiency), Sarcosinosis, Prolinemia |
| C. Adult onset | Possible adult onset: yes (hyperprolinemia types I and II) — hyperprolinemia may first be diagnosed in adulthood with psychosis or schizophrenia-like symptoms or with complications of kidney disease. Because the clinical impact of sarcosinemia and hydroxyprolinemia is uncertain, first diagnosis in adults is also possible. |
| 1. History | 1960s: first description of each disease → 1980s–90s: enzymes identified → 2000s: PRODH, ALDH4A1 and SARDH gene analysis → 2010s: active research on the hyperprolinemia–schizophrenia association. |
| 2. Causes | ① Sarcosinemia: SARDH (9q33.3) variants, sarcosine dehydrogenase deficiency. ② Hydroxyprolinemia: HOGA1 (10q24.2)-related. ③ Hyperprolinemia I: PRODH (22q11.21) variants, proline dehydrogenase deficiency. ④ Hyperprolinemia II: ALDH4A1 (1p36.13) variants, P5C dehydrogenase deficiency. |
| 3. Genetics | All autosomal recessive (some dominant with incomplete penetrance). PRODH is located within 22q11.21 (overlapping with 22q11.2 deletion syndrome). ALDH4A1: 1p36.13. SARDH: 9q33.3. |
| 4. General epidemiology | Each is ultra-rare. Hyperprolinemia I and II: tens to hundreds of cases reported. Sarcosinemia: about 30 cases or fewer. Hydroxyprolinemia: tens of cases. No sex difference. |
| 5. Pathophysiology | Each enzyme deficiency → accumulation of the substrate amino acid → neurotoxicity (hyperprolinemia), competition for renal tubular reabsorption (aminoaciduria), disturbance of GABA/glutamate metabolism (P5C accumulation in hyperprolinemia type II). |
| 6. Symptoms | Hyperprolinemia I: seizures and neurological abnormalities (many asymptomatic). Type II: seizures, developmental delay, P5C toxicity. Sarcosinemia: mostly asymptomatic. Hydroxyprolinemia: mostly asymptomatic or kidney stones. |
| 7. Signs | Specific elevation of plasma amino acids. Urinary aminoaciduria (hyperprolinemia: iminoglycinuria of proline, hydroxyproline and glycine). Type II: P5C (pyrroline-5-carboxylic acid) detected in urine. |
| 8. Screening | Can be detected on newborn MS/MS by elevation of the relevant amino acid. Hyperprolinemia: elevated plasma proline. Sarcosinemia: elevated plasma sarcosine. |
| 9. Diagnosis | Quantitative plasma amino acids (proline/sarcosine/hydroxyproline), urine amino acids and organic acids, molecular genetic testing (PRODH/ALDH4A1/SARDH). Urine P5C (diagnostic for type II). |
| 10. Treatment | Hyperprolinemia: low-proline diet (efficacy unclear), seizure control. Sarcosinemia and hydroxyprolinemia: no specific treatment. Trial of vitamin B6 (some type II). |
| 11. Prognosis | Sarcosinemia and hydroxyprolinemia: mostly good. Hyperprolinemia I: asymptomatic to mild neurological abnormalities. Type II: seizures and developmental delay are the main prognostic factors. |
| 12. Prevention | Genetic counseling, prenatal diagnosis. Early treatment of seizures when hyperprolinemia type II is confirmed. Elimination of causes of secondary hyperprolinemia (kidney disease, drugs). |
| 13. References | Phang JM et al. 2001; Jacquet H et al. 2002; Bender HU et al. 2005 and 7 other references. |
Disorders of glycine and proline metabolism are a heterogeneous group of diseases comprising several distinct enzyme deficiency disorders. The history of these diseases began mainly with advances in amino acid analysis technology in the 1960s–70s.
The first description of hyperprolinemia originates from the 1961 report by Self and Mainderer of elevated plasma proline in a patient with neurological abnormalities and kidney disease. It was later confirmed that hyperprolinemia is divided into two biochemical phenotypes. Enzyme studies in the 1970s–80s showed that type I is due to deficiency of proline oxidation (proline dehydrogenase, PRODH) and type II to deficiency of pyrroline-5-carboxylate dehydrogenase (P5C dehydrogenase, ALDH4A1). As it became known from the 1990s onward that the PRODH gene is located in the microdeletion region of the long arm of chromosome 22 (22q11.21), it was recognized that hyperprolinemia type I is sometimes observed in patients with 22q11.2 deletion syndrome (DiGeorge/Velocardiofacial syndrome). Since the 2000s, as research on the association between hyperprolinemia and schizophrenia/psychosis has drawn attention, PRODH gene variants have been investigated as one of the risk factors for schizophrenia.
Sarcosinemia was first reported in 1966 by Elias and colleagues in a child with elevated plasma sarcosine (N-methylglycine). It is caused by deficiency of sarcosine dehydrogenase (SARDH), and subsequent studies confirmed that most patients have no clinically significant symptoms. Hydroxyprolinemia was first reported in 1961 and was shown to be caused by deficiency of an enzyme of 4-hydroxyproline metabolism; most cases are asymptomatic, or kidney stones are reported as the only complication.
Since the 2000s, advances in next-generation sequencing (NGS) technology have systematized the molecular genetics of these diseases, and in particular the diverse variant spectrum of the PRODH gene (22q11.21) and the diversity of clinical phenotypes have become clear. The association between ALDH4A1 gene variants and hyperprolinemia type II was also established in the 2000s through several family studies.
This group of diseases includes several genetic disorders caused by different enzyme deficiencies in the glycine and proline metabolic pathways.
Hyperprolinemia type I: Pathogenic variants in the PRODH gene (22q11.21) reduce the function of the FAD-dependent inner mitochondrial membrane enzyme proline dehydrogenase (PRODH; EC 1.5.99.8). PRODH catalyzes the first step, the oxidation of proline to pyrroline-5-carboxylic acid (P5C). With PRODH deficiency, plasma proline rises markedly (normal 100–450 µmol/L → type I > 450–1000 µmol/L). Because the PRODH gene is located within 22q11.21, hemizygous PRODH deficiency can occur in patients with 22q11.2 microdeletion syndrome.
Hyperprolinemia type II: Pathogenic variants in the ALDH4A1 gene (1p36.13) cause loss of function of the mitochondrial enzyme pyrroline-5-carboxylate dehydrogenase (P5C dehydrogenase, P5CDH; EC 1.2.1.88). P5CDH catalyzes the step converting P5C to glutamate. When deficient, P5C accumulates in excess and plasma proline rises even more markedly (> 2000 µmol/L). P5C itself is thought to contribute to neurotoxicity and seizure induction.
Sarcosinemia: Pathogenic variants in the SARDH gene (9q33.3) cause deficient function of the mitochondrial enzyme sarcosine dehydrogenase (SARDH), and sarcosine (N-methylglycine) accumulates in plasma and urine. Sarcosine is an intermediate metabolite associated with folate metabolism. Because most patients with sarcosinemia have no specific clinical symptoms, whether it is pathogenic is controversial.
Hydroxyprolinemia: 4-Hydroxyproline accumulates due to deficiency of an enzyme of the 4-hydroxyproline oxidation pathway (HOGA1 gene, etc.). Most cases are asymptomatic or present as primary hyperhydroxyprolinuria. Kidney stone formation is rarely reported.
The PRODH gene is located on the long arm of chromosome 22 (22q11.21) and consists of 15 exons. Because this locus is included in the typical deleted region of 22q11.2 deletion syndrome (DiGeorge/Velocardiofacial syndrome), PRODH hemizygosity occurs in patients with the 22q11.2 deletion. In fact, hyperprolinemia type I is observed in some patients with 22q11.2 deletion syndrome, and this is being studied as one of the factors contributing to the neuropsychiatric phenotype of the syndrome (increased risk of schizophrenia). Some single nucleotide variants (SNPs) of the PRODH gene (e.g., Arg453Cys, Leu441Pro) have been reported to be associated with schizophrenia risk.
The ALDH4A1 gene is located on the short arm of chromosome 1 (1p36.13) and has 16 exons. It is a member of the NAD+-dependent aldehyde dehydrogenase superfamily. Tens of pathogenic variants have been reported to date, with missense, nonsense and splicing variants reported evenly. The SARDH gene is located on the long arm of chromosome 9 (9q33.3) and has 10 exons. Sarcosine dehydrogenase is a FAD-dependent enzyme bound to the inner mitochondrial membrane.
All diseases in this group have an autosomal recessive mode of inheritance. However, certain PRODH gene variants show incomplete penetrance and variable expressivity, so clinical features can differ greatly even among family members with the same variant. Molecular genetic testing is performed with NGS-based panels or targeted analysis of the relevant gene.
Each disease in this group is ultra-rare, with tens to hundreds of cases reported worldwide. There is no sex difference.
Hyperprolinemia type I: The exact incidence is not known, but hundreds of cases have been reported in the literature. Because the PRODH gene is located at 22q11.21, hemizygous PRODH deficiency may commonly accompany 22q11.2 deletion syndrome (incidence about 1:4,000–1:6,000), so the frequency encountered in actual clinical practice may be somewhat higher than for other ultra-rare diseases. Overall prevalence is unclear because there is no systematic population-based screening.
Hyperprolinemia type II: An ultra-rare disease with 50 or fewer cases reported in the literature. It occurs sporadically worldwide, with no clear clustering in particular ethnic groups or regions. Because seizures and developmental delay are more common in type II patients, type II must be differentiated when hyperprolinemia of unclear cause is found in neurology or pediatric practice.
Sarcosinemia: An ultra-rare disease with about 30 or fewer cases reported worldwide. Because sarcosine is also secondarily elevated in folate deficiency, it is important to distinguish primary SARDH deficiency from secondary causes. Hydroxyprolinemia has been reported in tens of cases and is mostly assessed as clinically harmless.
Pathophysiology of hyperprolinemia type I: Plasma proline rises due to PRODH deficiency. Proline is a precursor of the neurotransmitter glutamate and a neuromodulator, and there is a hypothesis that high proline concentrations competitively inhibit glutamate reuptake transporters (EAAT), possibly causing excess glutamate in the synapse. Proline also indirectly affects GABA metabolism. However, evidence on whether elevated proline is pathogenically significant in type I is still incomplete. The fact that many type I patients are asymptomatic raises doubts about a simple causal relationship. In the context of 22q11.2 deletion syndrome, the possibility that PRODH deficiency acts synergistically with the loss of other 22q11.2 genes is being studied.
Pathophysiology of hyperprolinemia type II: P5C (pyrroline-5-carboxylic acid) accumulates in excess due to ALDH4A1 deficiency. P5C can react with pyridoxal phosphate (the active form of vitamin B6) to form a complex and inactivate vitamin B6. Because vitamin B6 is an essential cofactor for dozens of enzyme reactions, vitamin B6 depletion by P5C is proposed as the key mechanism explaining seizures (inhibition of GABA synthesis) and neurodevelopmental impairment. Detection of P5C in urine is used as a specific diagnostic marker for type II.
Sarcosinemia and hydroxyprolinemia: No independent neurotoxic mechanism has been established for either disease to date. Effects of sarcosine excess on folate/methylation metabolism have been proposed theoretically, but clinical evidence is lacking. In hydroxyprolinemia, accumulated hydroxyproline may compete with normal amino acids for reabsorption in the renal tubules, causing aminoaciduria.
Symptoms of hyperprolinemia type I: Many patients are asymptomatic and are found incidentally through newborn screening or family investigation. Seizures, intellectual disability and behavioral abnormalities have been reported in some patients, but it is unclear whether these are the result of hyperprolinemia itself or the influence of other coexisting conditions. When accompanied by 22q11.2 deletion syndrome, cardiac anomalies, cleft palate, immunodeficiency, learning disabilities and increased risk of schizophrenia occur, but these are the broader phenotype of the 22q11.2 deletion rather than PRODH deficiency. The current consensus is close to the view that type I alone is often associated with mild or no neurological abnormalities. Some systematic studies have reported psychiatric phenotypes associated with type I (mild cognitive decline, social problems), but an independent association has not yet been established.
Symptoms of hyperprolinemia type II: It shows a much more severe clinical phenotype than type I. Developmental delay appears from infancy, and seizures (especially febrile seizures and complex partial seizures) are characteristic. Intellectual disability and learning problems become evident at school age. Because seizures arise by a mechanism similar to vitamin B6 deficiency, differentiation from pyridoxine-responsive seizures is necessary. In some patients, seizures partially improve with high-dose pyridoxine.
Symptoms of sarcosinemia: Most patients with sarcosinemia reported to date have no or mild clinical symptoms. Early reports described neurodevelopmental abnormalities, but later studies have questioned whether sarcosinemia is an independent clinical disease. The possibility of secondary sarcosine elevation due to folate deficiency or other metabolic abnormalities must always be differentiated.
Symptoms of hydroxyprolinemia: Mostly asymptomatic. Clinically significant neurological abnormalities are rare in primary hydroxyprolinemia, and kidney stone formation is rarely reported. Because its clinical significance is unclear, it tends to be interpreted as a metabolic abnormality close to a 'normal variant'.
Laboratory findings: Quantitative plasma amino acid analysis is the most important first-line diagnostic tool.
Neurological signs (hyperprolinemia type II): Seizures (complex partial seizures, clonic seizures, myoclonic seizures), developmental delay, hypotonia (in some patients). Generalized slow waves and epileptiform discharges on EEG. Brain MRI may be normal or show mild cortical abnormalities.
Hyperprolinemia may be detected on newborn tandem mass spectrometry (MS/MS) screening by elevated plasma proline (Pro) concentration. However, some countries do not include proline in the standard newborn screening panel, so screening systems differ by country. Sarcosine can also be measured by MS/MS, but its inclusion in screening panels is limited.
When plasma amino acids are used as the first-line screening tool, differentiation from secondary causes of hyperprolinemia (secondary elevation due to renal dysfunction, transient elevation after strenuous exercise, physiological neonatal hyperprolinemia, etc.) is necessary. Repeat measurement and assessment of the clinical context are important. Urine P5C testing for confirmation of type II is available at specialized biochemical testing laboratories.
When there is a family history (a confirmed sibling), performing molecular genetic testing first is most efficient. In patients with 22q11.2 deletion syndrome, assessing PRODH hemizygosity may be clinically meaningful.
The diagnosis is confirmed by combined biochemical and molecular genetic testing.
Quantitative plasma amino acid analysis: Plasma proline concentration is key to differentiating hyperprolinemia types I and II. Type I (450–1000 µmol/L) vs. type II (> 1000–5000 µmol/L). Sarcosinemia: measurement of plasma sarcosine (ion-exchange chromatography or LC-MS/MS).
Urine amino acid analysis: Iminoglycinuria of proline, hydroxyproline and glycine (hyperprolinemia types I and II). Qualitative and quantitative P5C testing (specific for type II).
Molecular genetic testing: NGS analysis of PRODH (type I), ALDH4A1 (type II) and SARDH (sarcosinemia) is the standard for confirmation. Chromosomal microarray (CMA) analysis including the 22q11.2 region confirms a 22q11.2 deletion encompassing PRODH.
Measurement of enzyme activity: PRODH or P5CDH enzyme activity can be measured in lymphoblasts or fibroblasts, but its role has diminished with advances in molecular diagnosis.
Folate metabolism tests (sarcosinemia): Testing of folate–methionine metabolism markers such as serum folate, homocysteine and methylmalonic acid is necessary to differentiate secondary sarcosinuria.
Established specific treatments for this group of diseases are limited, and management centers mainly on symptom control and dietary management.
Hyperprolinemia type I: There is no specific treatment, and follow-up observation alone is sufficient in most cases. The effect of a low-proline diet in asymptomatic patients is unclear. When seizures are present, they are controlled with standard antiepileptic drugs. In the context of 22q11.2 deletion syndrome, comprehensive management of the deletion takes priority.
Hyperprolinemia type II: To correct vitamin B6 depletion caused by P5C toxicity, administration of high-dose pyridoxine (Vitamin B6) (50–200 mg/day) is tried. Reduced seizure frequency has been reported in some patients, but it is not effective in all patients. A low-proline diet may lower plasma proline, but its effect on neurodevelopment is uncertain. Seizures are controlled with standard antiepileptic drugs; valproic acid is used cautiously because some studies have reported that it may worsen P5C accumulation.
Sarcosinemia: No specific treatment is needed to date. If there are secondary causes (folate deficiency, drugs), eliminating the cause takes priority. Folate supplementation may help lower sarcosine levels in secondary sarcosinemia.
Hydroxyprolinemia: No specific treatment needed. General advice such as increased fluid intake to prevent kidney stones may be provided.
Prognosis of hyperprolinemia type I: Most have an asymptomatic or mild phenotype, and the overall prognosis is good. When accompanied by 22q11.2 deletion syndrome, the prognosis is dominated by the extent of the deletion and the genes included. Many patients with isolated PRODH deficiency have normal neurodevelopment, but mild cognitive decline has been reported in small studies.
Prognosis of hyperprolinemia type II: Early diagnosis and treatment of seizures and pyridoxine responsiveness are key to prognosis. In pyridoxine-responsive patients, seizure control and developmental course are relatively favorable. Untreated recurrent seizures have a cumulative adverse effect on neurodevelopment. Mild to moderate intellectual disability remains in some patients.
Prognosis of sarcosinemia and hydroxyprolinemia: According to current evidence, the prognosis of both diseases is good, and most patients lead normal lives without specific treatment. Long-term natural history data are lacking, limiting complete prognostic assessment.
Primary prevention: Because all of these diseases are autosomal recessive, carrier testing and genetic counseling of patients' families are important. Occurrence in the next generation can be prevented through prenatal diagnosis (CVS or amniocentesis) or preimplantation genetic testing (PGT). In families with 22q11.2 deletion syndrome, checking for deletion of the region including the PRODH gene is recommended.
Secondary prevention (hyperprolinemia type II): Immediately upon confirmation, a pyridoxine trial and antiepileptic prescription are started to prevent neurological damage due to seizures. Caution is exercised in choosing drugs that may affect P5C metabolism, such as valproic acid.
Elimination of secondary causes: Secondary causes of hyperprolinemia (chronic kidney disease, folate deficiency, certain drugs) are identified and eliminated. In sarcosinemia as well, accompanying abnormalities of folate metabolism are corrected.
Phang JM, Hu CA, Valle D. Disorders of proline and hydroxyproline metabolism. In: Scriver CR et al., eds. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. McGraw-Hill; 2001:1821-1838.
Jacquet H, Demily C, Houy E, et al. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol Psychiatry. 2005;10(5):479-485. DOI: 10.1038/sj.mp.4001597. PMID: 15627644.
Bender HU, Almashanu S, Steel G, et al. Functional consequences of PRODH missense mutations. Am J Hum Genet. 2005;76(3):409-420. DOI: 10.1086/428142. PMID: 15666244.
Flynn MP, Martin MC, Moore PT, et al. Type II hyperprolinaemia in a pedigree of Irish travellers (nomads). Arch Dis Child. 1989;64(12):1699-1707. DOI: 10.1136/adc.64.12.1699. PMID: 2610674.
Goodman SI, Markey SP. Sarcosinemia. In: Diagnosis of Organic Acidemias by Gas Chromatography-Mass Spectrometry. Alan R. Liss; 1981:107-110.
Luder AS, Greene CL, Millington DS, et al. Hyperprolinemia type 2: report of a patient detected by newborn screening. J Inherit Metab Dis. 1992;15(5):688-690. DOI: 10.1007/BF01800105. PMID: 1287244.
Pandit B, Bhatt N, Mohan N, et al. Hyperprolinemia type II in a child with autism spectrum disorder and ALDH4A1 gene variant in a consanguineous family. Front Pediatr. 2025;13:1521489. DOI: 10.3389/fped.2025.1521489. PMID: 40007543.
Phang JM, Liu W, Hancock CN, et al. Proline metabolism and cancer: emerging links to glutamine and collagen. Curr Opin Clin Nutr Metab Care. 2015;18(1):71-77. DOI: 10.1097/MCO.0000000000000121. PMID: 25415183.
Tsiaras WG, Pueschel S, Kaye E, et al. Iminoglycinuria and its inheritance. Pediatrics. 1989;83(4):643-647. PMID: 2648738.
Yano S, Moseley K, Pavlova Z. Hydroxyproline metabolism in hyperprolinemia. J Inherit Metab Dis. 2007;30(2):201-206. DOI: 10.1007/s10545-007-0428-7. PMID: 17245631.